Clinical and analytical relevance of NNRTIs minority mutations on viral failure in HIV-1 infected patients

Journal of Medical Virology

Volumn 86, Issue 3, 2014, Pages 394-403

  Mohamed, Sofiane ^a,b   Ravet, Sophie ^c   Camus, Claire ^a   Khiri, Hacène ^a   Olive, Daniel ^b   Halfon, Philippe ^a,d  

^a Laboratoire Alphabio   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c CDL Pharma   (France)

^d Unité de médecine interne Hôpital européen   (France)

Author keywords

HIV; Minority mutations; NNRTIs; Pyrosequencing

Indexed keywords

EFAVIRENZ; ETRAVIRINE; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; TENOFOVIR;

ARTICLE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; GENETIC PROCEDURES; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; NONHUMAN; PYROSEQUENCING; RETROSPECTIVE STUDY; SANGER SEQUENCING; SENSITIVITY ANALYSIS; VIRUS MUTATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

HIV; MINORITY MUTATIONS; NNRTIS; PYROSEQUENCING;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MUTATION, MISSENSE; TREATMENT FAILURE;

EID: 84891927912     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23853     Document Type: Article

References (59)

1. Ahmadian A, Ehn M, Hober S. 2006. Pyrosequencing: History, biochemistry and future. Clin Chim Acta 363:83-94.
2. Asahchop EL, Oliveira M, Wainberg MA, Brenner BG, Moisi D, Toni T, Tremblay CL. 2011. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob Agents Chemother 55:600-607.
3. Azijn H, Tirry I, Vingerhoets J, de Bethune MP, Kraus G, Boven K, Jochmans D, Van Craenenbroeck E, Picchio G, Rimsky LT. 2010. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 54:718-727.
4. Boyer PL, Currens MJ, McMahon JB, Boyd MR, Hughes SH. 1993. Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J Virol 67:2412-2420.
5. Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M, Marlink RG, Schapiro J, Roger M, Wainberg MA. 2003. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 17:F1-F5.
6. Briones C, Domingo E. 2008. Minority report: Hidden memory genomes in HIV-1 quasispecies and possible clinical implications. AIDS Rev 10:93-109.
7. Church JD, Jones D, Flys T, Hoover D, Marlowe N, Chen S, Shi C, Eshleman JR, Guay LA, Jackson JB, Kumwenda N, Taha TE, Eshleman SH. 2006. Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. J Mol Diagn 8:430-432; quiz 527.
8. Condra JH, Holder DJ, Schleif WA, Blahy OM, Danovich RM, Gabryelski LJ, Graham DJ, Laird D, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Yang T, Chodakewitz JA, Deutsch PJ, Leavitt RY, Massari FE, Mellors JW, Squires KE, Steigbigel RT, Teppler H, Emini EA. 1996. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 70:8270-8276.
9. Condra JH. 1998. Resistance to HIV protease inhibitors. Haemophilia 4:610-615.
10. Craig DW, Pearson JV, Szelinger S, Sekar A, Redman M, Corneveaux JJ, Pawlowski TL, Laub T, Nunn G, Stephan DA, Homer N, Huentelman MJ. 2008. Identification of genetic variants using bar-coded multiplexed sequencing. Nat Methods 5:887-893.
11. Demeter LM, D'Aquila R, Weislow O, Lorenzo E, Erice A, Fitzgibbon J, Shafer R, Richman D, Howard TM, Zhao Y, Fisher E, Huang D, Mayers D, Sylvester S, Arens M, Sannerud K, Rasheed S, Johnson V, Kuritzkes D, Reichelderfer P, Japour A. 1998. Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group. J Virol Methods 75:93-104.
12. Deshpande A, Jauvin V, Magnin N, Pinson P, Faure M, Masquelier B, Aurillac-Lavignolle V, Fleury HJ. 2007. Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: Resistance to AR. AIDS Res Hum Retroviruses 23:335-340.
13. Doostzadeh J, Shokralla S, Absalan F, Jalili R, Mohandessi S, Langston JW, Davis RW, Ronaghi M, Gharizadeh B. 2008. High throughput automated allele frequency estimation by pyrosequencing. PLoS ONE 3:e2693.
14. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM, Dellamonica P. 1999. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. Lancet 353:2195-2199.
15. Elahi E, Pourmand N, Chaung R, Rofoogaran A, Boisver J, Samimi-Rad K, Davis RW, Ronaghi M. 2003. Determination of hepatitis C virus genotype by Pyrosequencing. J Virol Methods 109:171-176.
16. Fisher R, van Zyl GU, Travers SA, Kosakovsky Pond SL, Engelbrech S, Murrell B, Scheffler K, Smith D. 2012. Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen. J Virol 86:6231-6237.
17. Garcia-Gonzalez C, Garcia-Bujalance S, Ruiz-Carrascoso G, Arribas JR, Gonzalez-Garcia J, Bernardino JI, Pascual-Pareja JF, Martinez-Prats L, Delgado R, Mingorance J. 2012. Detection and quantification of the K103N mutation in HIV reverse transcriptase by pyrosequencing. Diagn Microbiol Infect Dis 72:90-96.
18. Geretti AM, Fox ZV, Booth CL, Smith CJ, Phillips AN, Johnson M, Li JF, Heneine W, Johnson JA. 2009. Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr 52:569-573.
19. Gharizadeh B, Kalantari M, Garcia CA, Johansson B, Nyren P. 2001. Typing of human papillomavirus by pyrosequencing. Lab Invest 81:673-679.
20. Halfon P, Durant J, Clevenbergh P, Carsenti H, Celis L, Khiri H, De Smet K, De Brauwer A, Hulstaert F, Dellamonica P. 2003. Kinetics of disappearance of resistance mutations and reappearance of wild-type during structured treatment interruptions. AIDS 17:1351-1361.
21. Halvas EK, Aldrovandi GM, Balfe P, Beck IA, Boltz VF, Coffin JM, Frenkel LM, Hazelwood JD, Johnson VA, Kearney M, Kovacs A, Kuritzkes DR, Metzner KJ, Nissley DV, Nowicki M, Palmer S, Ziermann R, Zhao RY, Jennings CL, Bremer J, Brambilla D, Mellors JW. 2006. Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol 44:2612-2614.
22. Harrigan PR, Mo T, Wynhoven B, Hirsch J, Brumme Z, McKenna P, Pattery T, Vingerhoets J, Bacheler LT. 2005. Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 19:549-554.
23. Havlir DV, Eastman S, Gamst A, Richman DD. 1996. Nevirapine-resistant human immunodeficiency virus: Kinetics of replication and estimated prevalence in untreated patients. J Virol 70:7894-7899.
24. Henn MR, Boutwell CL, Charlebois P, Lennon NJ, Power KA, Macalalad AR, Berlin AM, Malboeuf CM, Ryan EM, Gnerre S, Zody MC, Erlich RL, Green LM, Berical A, Wang Y, Casali M, Streeck H, Bloom AK, Dudek T, Tully D, Newman R, Axten KL, Gladden AD, Battis L, Kemper M, Zeng Q, Shea TP, Gujja S, Zedlack C, Gasser O, Brander C, Hess C, Gunthard HF, Brumme ZL, Brumme CJ, Bazner S, Rychert J, Tinsley JP, Mayer KH, Rosenberg E, Pereyra F, Levin JZ, Young SK, Jessen H, Altfeld M, Birren BW, Walker BD, Allen TM. 2012. Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog 8:e1002529.
25. Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter LM, Vella S, Jacobsen DM, Richman DD. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. JAMA 283:2417-2426.
26. Hsiou Y, Ding J, Das K, Clark AD, Jr., Boyer PL, Lewi P, Janssen PA, Kleim JP, Rosner M, Hughes SH, Arnold E. 2001. The Lys103Asn mutation of HIV-1 RT: A novel mechanism of drug resistance. J Mol Biol 309:437-445.
27. Hyman ED. 1988. A new method of sequencing DNA. Anal Biochem 174:423-436.
28. Jackson JB, Becker-Pergola G, Guay LA, Musoke P, Mracna M, Fowler MG, Mofenson LM, Mirochnick M, Mmiro F, Eshleman SH. 2000. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 14:F111-115.
29. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, Craig C, Smith A, Bennett DE, Monsour M, Sandstrom P, Lanier ER, Heneine W. 2008. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 5:e158.
30. Kagan RM, Johnson EP, Siaw M, Biswas P, Chapman DS, Su Z, Platt JL, Pesano RL. 2012. A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients. PLoS ONE 7:e46334.
31. Lambert-Niclot S, Charpentier C, Storto A, Fofana DB, Soulie C, Fourati S, Visseaux B, Wirden M, Morand-Joubert L, Masquelier B, Flandre P, Calvez V, Descamps D, Marcelin AG. 2013. Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses. J Antimicrob Chemother 68:1237-1242.
32. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, Henfrey RD. 1993. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 365:671-673.
33. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, Hullsiek KH, Balduin M, Jakobsen MR, Geretti AM, Thiebaut R, Ostergaard L, Masquelier B, Johnson JA, Miller MD, Kuritzkes DR. 2011. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: A systematic review and pooled analysis. JAMA 305:1327-1335.
34. Li JZ, Paredes R, Ribaudo HJ, Kozal MJ, Svarovskaia ES, Johnson JA, Geretti AM, Metzner KJ, Jakobsen MR, Hullsiek KH, Ostergaard L, Miller MD, Kuritzkes DR. 2013. Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. J Infect Dis 207:893-897.
35. Lindstrom A, Odeberg J, Albert J. 2004. Pyrosequencing for detection of lamivudine-resistant hepatitis B virus. J Clin Microbiol 42:4788-4795.
36. Llibre JM, Schapiro JM, Clotet B. 2010. Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure. Clin Infect Dis 50:872-881.
37. Mackie N. 2006. Resistance to non-nucleoside reverse transcriptase inhibitors. In: Geretti AM, editor. Antiretroviral Resistance in Clinical Practice. London.
38. Maiga AI, Descamps D, Morand-Joubert L, Malet I, Derache A, Cisse M, Koita V, Akonde A, Diarra B, Wirden M, Tounkara A, Verlinden Y, Katlama C, Costagliola D, Masquelier B, Calvez V, Marcelin AG. 2010. Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naive patients infected with non-B HIV-1 subtypes. Antimicrob Agents Chemother 54:728-733.
39. Marcelin AG, Flandre P, Descamps D, Morand-Joubert L, Charpentier C, Izopet J, Trabaud MA, Saoudin H, Delaugerre C, Tamalet C, Cottalorda J, Bouvier-Alias M, Bettinger D, Dos Santos G, Ruffault A, Alloui C, Henquell C, Rogez S, Barin F, Signori-Schmuck A, Vallet S, Masquelier B, Calvez V. 2010. Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients. Antimicrob Agents Chemother 54:72-77.
40. Mardis ER. 2008. Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet 9:387-402.
41. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. 2008. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 22:1971-1977.
42. Molla A, Granneman GR, Sun E, Kempf DJ. 1998. Recent developments in HIV protease inhibitor therapy. Antiviral Res 39:1-23.
43. O'Meara D, Wilbe K, Leitner T, Hejdeman B, Albert J, Lundeberg J. 2001. Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing. J Clin Microbiol 39:464-473.
44. Ojesina AI, Sankale JL, Odaibo G, Langevin S, Meloni ST, Sarr AD, Olaleye D, Kanki PJ. 2006. Subtype-specific patterns in HIV Type 1 reverse transcriptase and protease in Oyo State, Nigeria: implications for drug resistance and host response. AIDS Res Hum Retroviruses 22:770-779.
45. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, Rock D, Falloon J, Davey RT, Jr., Dewar RL, Metcalf JA, Hammer S, Mellors JW, Coffin JM. 2005. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 43:406-413.
46. Piot P, Quinn TC. 2013. Response to the AIDS pandemic-A global health model. N Engl J Med 368:2210-2218.
47. Pourmand N, Elahi E, Davis RW, Ronaghi M. 2002. Multiplex pyrosequencing. Nucleic Acids Res 30:e31.
48. Rimsky L, Vingerhoets J, Van Eygen V, Eron J, Clotet B, Hoogstoel A, Boven K, Picchio G. 2012. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr 59:39-46.
49. Ronaghi M, Karamohamed S, Pettersson B, Uhlen M, Nyren P. 1996. Real-time DNA sequencing using detection of pyrophosphate release. Anal Biochem 242:84-89.
50. Ronaghi M, Pettersson B, Uhlen M, Nyren P. 1998a. PCR-introduced loop structure as primer in DNA sequencing. Biotechniques 25:876-878, 880-872, 884.
51. Ronaghi M, Uhlen M, Nyren P. 1998b. A sequencing method based on real-time pyrophosphate. Science 281:363-365.
52. Rothberg JM, Leamon JH. 2008. The development and impact of 454 sequencing. Nat Biotechnol 26:1117-1124.
53. Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, de Groot T, Boucher C. 1999. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol 37:2291-2296.
54. Stelzl E, Proll J, Bizon B, Niklas N, Danzer M, Hackl C, Stabentheiner S, Gabriel C, Kessler HH. 2011. Human immunodeficiency virus type 1 drug resistance testing: Evaluation of a new ultra-deep sequencing-based protocol and comparison with the TRUGENE HIV-1 Genotyping Kit. J Virol Methods 178:94-97.
55. Vingerhoets J, Azijn H, Fransen E, De Baere I, Smeulders L, Jochmans D, Andries K, Pauwels R, de Bethune MP. 2005. TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments. J Virol 79:12773-12782.
56. Vingerhoets J, Tambuyzer L, Azijn H, Hoogstoel A, Nijs S, Peeters M, de Bethune MP, De Smedt G, Woodfall B, Picchio G. 2010. Resistance profile of etravirine: Combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 24:503-514.
57. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag SS, Shaw MG. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
58. Zagordi O, Klein R, Daumer M, Beerenwinkel N. 2010. Error correction of next-generation sequencing data and reliable estimation of HIV quasispecies. Nucleic Acids Res 38:7400-7409.
59. Zagordi O, Daumer M, Beisel C, Beerenwinkel N. 2012. Read length versus depth of coverage for viral quasispecies reconstruction. PLoS ONE 7:e47046.